Stanley, Margaret A.
মার্গারেট স্ট্যানলি
VIAF ID: 15482255 (Personal)
Permalink: http://viaf.org/viaf/15482255
Preferred Forms
-
100 1 0
‡a
Stanley, Margaret A.
-
100 1 _ ‡a Stanley, Margaret A.
-
100 1 _
‡a
Stanley, Margaret A.
-
100 1 _
‡a
Stanley, Margaret A.
-
100 0 _
‡a
মার্গারেট স্ট্যানলি
4xx's: Alternate Name Forms (2)
Works
| Title | Sources |
|---|---|
| Anal cancer in women: are we appropriately identifying the risks? |
|
| Antibody reactivity to HPV E6 and E7 oncoproteins and early diagnosis of invasive cervical cancer |
|
| The Cape Town declaration on human papillomavirus related disease. |
|
| Critical evaluation of HPV16 gene copy number quantification by SYBR green PCR. |
|
| Early age of sexual debut: a risky experience |
|
| The end for genital human papillomavirus infections? |
|
| The epidemiology and burden of HPV disease |
|
| Estimation of the individual residual risk of cervical cancer after vaccination with the nonavalent HPV vaccine. |
|
| European consensus statement on "HPV Vaccination and Colposcopy". |
|
| Evaluation of the immunogenicity of the quadrivalent HPV vaccine using 2 versus 3 doses at month 21: An epidemiological surveillance mechanism for alternate vaccination schemes. |
|
| HPV single-dose vaccination: Impact potential, evidence base and further evaluation |
|
| HPV vaccination for victims of childhood sexual abuse |
|
| HPV vaccines: where are we now? |
|
| Immune intervention in HPV infections: current progress and future developments |
|
| Immunobiology of HPV and HPV vaccines |
|
| Immunology of human papillomaviruses |
|
| Infiltrating T-cell markers in cervical carcinogenesis: a systematic review and meta-analysis |
|
| Monitoring HPV vaccination |
|
| Overcoming barriers to HPV vaccination: non-inferiority of antibody response to human papillomavirus 16/18 vaccine in adolescents vaccinated with a two-dose vs. a three-dose schedule at 21 months |
|
| Persistence of immunity when using different HPV vaccination schedules and booster dose effects at 5 years post-primary vaccination |
|
| Perspective: Vaccinate boys too |
|
| Potential mechanisms for HPV vaccine-induced long-term protection |
|
| Preventing cervical cancer and genital warts - How much protection is enough for HPV vaccines? |
|
| Primary Prevention of Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Guideline |
|
| Prophylactic HPV vaccines |
|
| Prospects for the new HPV Prevention and Control Board. |
|
| Re: Letter to the Editor: P. van Damme et al., Vaccine 34 (2016) 757-761, as a reply to Ryser et al's letter in Vaccine. |
|
| Realities of alternative HPV vaccination schedules |
|
| Recurrent respiratory papillomatosis: an overview of current thinking and treatment |
|
| Reply to San Giorgi and Dikkers |
|
| Talking about human papillomavirus and cancer: development of consultation guides through lay and professional stakeholder coproduction using qualitative, quantitative and secondary data |
|
| Tumour virus vaccines: hepatitis B virus and human papillomavirus. |
|
| The use of HPV Linear Array Assay for multiple HPV typing on archival frozen tissue and DNA specimens |
|
| Use of the nonavalent HPV vaccine in individuals previously fully or partially vaccinated with bivalent or quadrivalent HPV vaccines |
|
